Intervention
Dasatinib
Mechanism, regulatory status, and an honest, tiered evidence map.
○ Human lifespan evidence: none (animal/preclinical or mechanism only)
What it is
Class: Tyrosine-kinase inhibitor (senolytic combination component)
Also known as: Sprycel (brand)
Relationship to senescence: An FDA-approved oncology tyrosine-kinase inhibitor used as the dasatinib partner in D+Q; targets tyrosine-kinase-dependent survival signalling in senescent cells (notably senescent preadipocytes).
Regulatory status
FDA-approved prescription drug for chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. NOT approved as a senolytic or for aging. Prescription-only; carries oncology-drug safety considerations.
Mechanism
Disables tyrosine-kinase survival networks; used intermittently and in combination, never as a standalone anti-aging therapy. See /dasatinib-quercetin.
Evidence — Human (only within D+Q pilots)
| Species / population | Studied as a senolytic only in combination pilots (IPF, DKD, Alzheimer's). |
| Exposure, route, schedule | 100 mg/day intermittently within D+Q protocols. |
| Comparator / duration | See D+Q study pages. |
| Endpoint / numeric result | Detected in CSF in the Alzheimer's pilot (0.281-0.536 ng/mL in 4/5 participants). |
| What it did NOT establish | No standalone senolytic outcome; oncology safety profile applies. |
Negative or null findings
- No evidence supports standalone dasatinib for any aging or longevity outcome.